Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1G | O43497 | 1/20 | 0.43 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.43 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6312719 | 0.89 | HSD11B1 (0.43) | HSD11B1S1PR5S1PR1GRIN2B | |
| SCHEMBL5746618 | 0.88 | HSD11B1 (0.46) | HSD11B1POLBS1PR5S1PR1GRIN2B | |
| SCHEMBL6310196 | 0.85 | CACNA1G (0.44) | CACNA1GCACNA1HCACNA1IPOLBS1PR5 | |
| SCHEMBL6310215 | 0.80 | CACNA1G (0.44) | CACNA1GCACNA1HCACNA1IPOLBS1PR5 | |
| SCHEMBL5748184 | 0.78 | HSD11B1 (0.41) | HSD11B1GRIN2BSIGMAR1 | |
| SCHEMBL5747642 | 0.77 | HSD11B1 (0.44) | HSD11B1POLBGRIN2BSIGMAR1 | |
| SCHEMBL6309403 | 0.75 | HSD11B1 (0.47) | HSD11B1S1PR5S1PR1GRIN2B | |
| SCHEMBL6317296 | 0.75 | DRD2 (0.41) | CACNA1GCACNA1HCACNA1IPOLBS1PR5 | |
| SCHEMBL5747422 | 0.74 | HSD11B1 (0.51) | HSD11B1S1PR5S1PR1GRIN2B | |
| SCHEMBL20587395 | 0.74 | AGTR2 (0.48) | HSD11B1S1PR5S1PR1TMEM97SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1638935-A1 | NK1 ANTAGONIST | Pfizer Products Inc. (US) | 2006-03-29 | — | — | EP | disclosed |
| US-20050043354-A1 | NK1 antagonist | PFIZER INC | 2005-02-24 | — | — | US | disclosed |
| WO-2004110996-A1 | NK1 ANTAGONIST | PFIZER PRODUCTS INC. (US) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043354-A1 | NK1 antagonist | TACR2, TACR1, TAC3 | CACNA1G 1297/4885CACNA1H 1149/4885CACNA1I 1335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.